ctDNA in Cutaneous Squamous Cell Carcinoma

Description

The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.

Conditions

Cutaneous Squamous Cell Carcinoma

Study Overview

Study Details

Study overview

The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.

ctDNA Clearance and ctDNA Monitoring Study in Cutaneous Squamous Cell Carcinoma

ctDNA in Cutaneous Squamous Cell Carcinoma

Condition
Cutaneous Squamous Cell Carcinoma
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts Eye and Ear, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with surgically resectable primary CSCC with PNI (\>0.1mm caliber nerve) or at least 2 high-risk features defined as size \> 2cm, recurrent CSCC, LVI, immunosuppressed, poorly differentiated, and/or invasion \>6mm/beyond subcutaneous fat;
  • * Patients with surgically resectable regional metastases not receiving neoadjuvant therapy
  • * Patients with Cutaneous Squamous Cell Carcinoma not amenable to surgical resection
  • * Patients receiving or undergoing systemic therapies.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts Eye and Ear Infirmary,

Sophia Z. Shalhout, PhD, PRINCIPAL_INVESTIGATOR, Massachusetts Eye and Ear

Study Record Dates

2029-04-30